|
시장보고서
상품코드
1800794
맥락막 신생혈관 시장 보고서 : 제품 유형, 진단 종류, 치료 종류, 용도, 지역별(2025-2033년)Choroidal Neovascularization Market Report by Product Type, Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), Treatment Type, Application, and Region 2025-2033 |
||||||
세계 맥락막 신생혈관 시장 규모는 2024년 69억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 122억 달러에 달해 2025년부터 2033년까지 6.13%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.
맥락막 신생혈관(CNV)은 눈의 맥락막층에 생긴 신생혈관으로, Bruch's membrane과 망막색소상피(RPE)에 영향을 미치는 신생혈관을 말합니다. 그 증상으로는 지질 삼출, 망막하 혈액이나 액체, 중심시야의 왜곡, 부풀어 오름, 흑점 등이 있습니다. 현재 CNV의 진단에는 플루오레세인 혈관조영술(FA), 인도시아닌그린(ICG) 혈관조영술, 광간섭단층촬영(OCT) 스캔 등의 검사가 병용되고 있습니다. 그 결과에 따라 의사는 항혈관내피성장인자(VEGF) 약물, 열 레이저 치료, 광역학 치료(PDT)를 처방하여 혈관의 성장을 막습니다.
노화성 황반변성(ARMD), 안구 히스토플라즈마증, 병적 근시, 혈관근육, 맥락막 파열, 맥락막 및 망막의 염증성 질환의 유병률 증가로 인해 시장이 성장하고 있습니다. 또한, 심각한 건강 상태에 빠지기 쉬운 노령 인구의 증가는 시장 성장을 촉진하는 중요한 요인으로 작용하고 있습니다. 또한, 장기 지속형 항VEGF 약물의 도입과 함께 병용요법의 도입이 증가하면서 CNV 치료에 대한 전 세계 수요를 견인하고 있습니다. 헬스케어 인프라 개선, 연구개발(R&D) 활동 투자 증가 등 다른 요인들도 시장 성장에 기여하고 있습니다.
본 보고서에서 다루는 주요 질문
- 세계 맥락막 신생혈관 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
- COVID-19가 세계 맥락막 신생혈관 시장에 미치는 영향은?
- 주요 지역 시장이란?
- 제품 유형별 시장 분석은?
- 진단 유형별 시장 현황은?
- 치료 유형별 시장 분석은?
- 용도별 시장 내역은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 맥락막 신생혈관 시장의 구조와 주요 기업은?
- 업계 내 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 1차 정보
- 2차 정보
- 시장 추정
- 상향식 접근
- 하향식 접근
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 맥락막 신생혈관 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 제품 유형별
- 정맥내
- 유리체내
제7장 시장 내역 : 진단 종류별
- 플루오레세인 형광 안저조영(FA)
- 인도시아닌 그린(ICG) 혈관조영
- 스펙트럼 영역 광간섭단층촬영(OCT)
- 기타
제8장 시장 내역 : 치료 종류별
- 혈관신생 억제제 주사제
- 광역학 요법
- 레이저 광응고술
- 저선량 방사선 치료
- 수술
제9장 시장 내역 : 용도별
- 극도 근시
- 악성 근시 변성증
- 노화에 의한 변화
제10장 시장 내역 : 지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- MaaT Pharma
- Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc.(SBI ALApharma Co., Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd.(SUZUKEN CO., LTD.)
The global choroidal neovascularization market size reached USD 6.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.13% during 2025-2033.
Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.
The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.
Key Market Segmentation:
Breakup by Product Type:
- Intravenous
- Intravitreal
Breakup by Type of Diagnosis:
- Fluorescein Angiography (FA)
- Indocyanine Green (ICG) Angiography
- Spectral Domain Optical Coherence Tomography (OCT)
- Others
Breakup by Treatment Type:
- Angiogenesis Inhibitors Injection
- Photodynamic Therapy
- Laser photocoagulation
- Low-dose Radiation Therapy
- Surgery
Breakup by Application:
- Extreme Myopia
- Malignant Myopic Degeneration
- Age-Related Developments
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).
Key Questions Answered in This Report:
- How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global choroidal neovascularization market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the type of diagnosis?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global choroidal neovascularization market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Choroidal Neovascularization Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Intravenous
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Intravitreal
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Type of Diagnosis
- 7.1 Fluorescein Angiography (FA)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Indocyanine Green (ICG) Angiography
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Spectral Domain Optical Coherence Tomography (OCT)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Treatment Type
- 8.1 Angiogenesis Inhibitors Injection
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Photodynamic Therapy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Laser Photocoagulation
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Low-dose Radiation Therapy
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Surgery
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Application
- 9.1 Extreme Myopia
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Malignant Myopic Degeneration
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Age-Related Developments
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Bausch Health Companies Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Bayer AG
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Gilead Sciences, Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche AG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 SWOT Analysis
- 15.3.5 MaaT Pharma
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited)
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Regeneron Pharmaceuticals Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.)
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.1 Bausch Health Companies Inc.
